Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immune response to SARS-CoV-2 variants of concern in vaccinated individuals

Matthias Becker, Alex Dulovic, Daniel Junker, Natalia Ruetalo, Philipp D. Kaiser, Yudi T. Pinilla, Constanze Heinzel, Julia Haering, Bjoern Traenkle, Teresa R. Wagner, Mirjam Layer, Martin Mehrlaender, Valbona Mirakaj, Jana Held, Hannes Planatscher, Katja Schenke-Layland, Gérard Krause, Monika Strengert, Tamam Bakchoul, Karina Althaus, Rolf Fendel, Andrea Kreidenweiss, Michael Koeppen, Ulrich Rothbauer, Michael Schindler, Nicole Schneiderhan-Marra
doi: https://doi.org/10.1101/2021.03.08.21252958
Matthias Becker
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Dulovic
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Junker
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalia Ruetalo
2Institute for Medical Virology and Epidemiology, University Hospital Tübingen, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp D. Kaiser
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yudi T. Pinilla
3Institute of Tropical Medicine, University of Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Constanze Heinzel
3Institute of Tropical Medicine, University of Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Haering
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bjoern Traenkle
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa R. Wagner
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
4Pharmaceutical Biotechnology, University of Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mirjam Layer
2Institute for Medical Virology and Epidemiology, University Hospital Tübingen, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Mehrlaender
5Department of Anaesthesiology and Intensive Care Medicine, University Hospital Tübingen, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valbona Mirakaj
5Department of Anaesthesiology and Intensive Care Medicine, University Hospital Tübingen, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jana Held
3Institute of Tropical Medicine, University of Tübingen, Germany
6German Center for Infection Research (DZIF), Partner Site Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hannes Planatscher
7Signatope GmbH, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katja Schenke-Layland
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
8Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen, Tübingen, Germany
9Department of Women’s Health, Research Institute for Women’s Health, University of Tübingen, Tübingen, Germany
10Department of Medicine/Cardiology, Cardiovascular Research Laboratories, David Geffen School of Medicine at UCLA, Los Angeles, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gérard Krause
11Helmholtz Centre for Infection Research, Braunschweig, Germany
12TWINCORE GmbH, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monika Strengert
11Helmholtz Centre for Infection Research, Braunschweig, Germany
12TWINCORE GmbH, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamam Bakchoul
13Institute for Clinical and Experimental Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karina Althaus
13Institute for Clinical and Experimental Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rolf Fendel
3Institute of Tropical Medicine, University of Tübingen, Germany
6German Center for Infection Research (DZIF), Partner Site Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Kreidenweiss
3Institute of Tropical Medicine, University of Tübingen, Germany
6German Center for Infection Research (DZIF), Partner Site Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Koeppen
5Department of Anaesthesiology and Intensive Care Medicine, University Hospital Tübingen, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Rothbauer
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
4Pharmaceutical Biotechnology, University of Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nicole.schneiderhan@nmi.de
Michael Schindler
2Institute for Medical Virology and Epidemiology, University Hospital Tübingen, Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nicole.schneiderhan@nmi.de
Nicole Schneiderhan-Marra
1NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nicole.schneiderhan@nmi.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The SARS-CoV-2 pandemic virus is consistently evolving with mutations within the receptor binding domain (RBD)1 being of particular concern2-4. To date, there is little research into protection offered following vaccination or infection against RBD mutants in emerging variants of concern (UK3, South African5, Mink6 and Southern California7). To investigate this, serum and saliva samples were obtained from groups of vaccinated (Pfizer BNT-162b28), infected and uninfected individuals. Antibody responses among groups, including salivary antibody response and antibody binding to RBD mutant strains were examined. The neutralization capacity of the antibody response against a patient-isolated South African variant was tested by viral neutralization tests and further verified by an ACE2 competition assay. We found that humoral responses in vaccinated individuals showed a robust response after the second dose. Interestingly, IgG antibodies were detected in large titers in the saliva of vaccinated subjects. Antibody responses showed considerable differences in binding to RBD mutants in emerging variants of concern. A substantial reduction in RBD binding and neutralization was detected for the South African variant. Taken together our data reinforces the importance of administering the second dose of Pfizer BNT-162b2 to acquire high levels of neutralizing antibodies. High antibody titers in saliva suggest that vaccinated individuals may have reduced transmission potential. Substantially reduced neutralization for the South African variant highlights importance of surveillance strategies to detect new variants and targeting these in future vaccines.

Competing Interest Statement

T.R.W., P.K., N.S.M. and U.R. are named as inventors on a patent application (EP 20 197 031.6) claiming the use of the described Nanobodies used in the NeutrobodyPlex for diagnosis and therapeutics filed by the Natural and Medical Sciences Institute. The other authors declare no competing interest.

Funding Statement

This work was financially supported by the State Ministry of Baden-Wuerttemberg for Economic Affairs, Labour and Housing Construction (grant numbers FKZ 3-4332.62-NMI-67 and FKZ 3-4332.62-NMI-68), the Ministerium for Wissenschaft und Kunst Baden-Wuerttemberg, the Initiative and Networking Fund of the Helmholtz Association of German Research Centres (grant number SO-96), the Deutsche Forschungsgemeinschaft (DFG-KO 3884/5-1) and the EU Horizon 2020 research and innovation programme (grant agreement number 101003480-CORESMA). The funders had no role in study design, data collection, data analysis or the decision to publish.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved the Ethics Committee of Eberhard Karls University and the University Hospital Tuebingen under the approval number 312/2020BO1 (Coro-Buddy) to Dr. Andrea Kreidenweiss, Institute for Tropical Medicine, University Hospital Tuebingen and Eberhard Karls University Tuebingen, and 312/2020BO2 to Dr. Karina Althaus, Institute for Clinical and Experimental Transfusion Medicine, University Hospital Tuebingen . All participants gave written informed consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Contact Information Nicole Schneiderhan-Marra – Phone number +49 (0)7121 51530 815. Postal Address – Markwiesenstrasse 55, 72770 Reutlingen, Germany.

  • Michael Schindler – Phone number +49 (0)7071 295790. Email Address Michael.Schindler{at}med.uni-tuebingen.de Postal Address – Elfriede-Aulhorn-Strasse 6, 72076 Tübingen, Germany

  • Ulrich Rothbauer – Phone number +49 (0)7121 51530 415. Email Address Ulrich.rothbauer{at}nmi.de Postal Address – Markwiesenstrasse 55, 72770 Reutlingen, Germany

  • Competing Interests T.R.W., P.K., N.S.M. and U.R. are named as inventors on a patent application (EP 20 197 031.6) claiming the use of the described Nanobodies used in the NeutrobodyPlex for diagnosis and therapeutics filed by the Natural and Medical Sciences Institute. The other authors declare no competing interest.

Data Availability

The original data, figure files and data analysis scripts are available upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 10, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
Matthias Becker, Alex Dulovic, Daniel Junker, Natalia Ruetalo, Philipp D. Kaiser, Yudi T. Pinilla, Constanze Heinzel, Julia Haering, Bjoern Traenkle, Teresa R. Wagner, Mirjam Layer, Martin Mehrlaender, Valbona Mirakaj, Jana Held, Hannes Planatscher, Katja Schenke-Layland, Gérard Krause, Monika Strengert, Tamam Bakchoul, Karina Althaus, Rolf Fendel, Andrea Kreidenweiss, Michael Koeppen, Ulrich Rothbauer, Michael Schindler, Nicole Schneiderhan-Marra
medRxiv 2021.03.08.21252958; doi: https://doi.org/10.1101/2021.03.08.21252958
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
Matthias Becker, Alex Dulovic, Daniel Junker, Natalia Ruetalo, Philipp D. Kaiser, Yudi T. Pinilla, Constanze Heinzel, Julia Haering, Bjoern Traenkle, Teresa R. Wagner, Mirjam Layer, Martin Mehrlaender, Valbona Mirakaj, Jana Held, Hannes Planatscher, Katja Schenke-Layland, Gérard Krause, Monika Strengert, Tamam Bakchoul, Karina Althaus, Rolf Fendel, Andrea Kreidenweiss, Michael Koeppen, Ulrich Rothbauer, Michael Schindler, Nicole Schneiderhan-Marra
medRxiv 2021.03.08.21252958; doi: https://doi.org/10.1101/2021.03.08.21252958

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (238)
  • Allergy and Immunology (519)
  • Anesthesia (124)
  • Cardiovascular Medicine (1407)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (580)
  • Epidemiology (10264)
  • Forensic Medicine (6)
  • Gastroenterology (526)
  • Genetic and Genomic Medicine (2611)
  • Geriatric Medicine (253)
  • Health Economics (495)
  • Health Informatics (1727)
  • Health Policy (788)
  • Health Systems and Quality Improvement (669)
  • Hematology (266)
  • HIV/AIDS (563)
  • Infectious Diseases (except HIV/AIDS) (12066)
  • Intensive Care and Critical Care Medicine (647)
  • Medical Education (272)
  • Medical Ethics (83)
  • Nephrology (286)
  • Neurology (2448)
  • Nursing (143)
  • Nutrition (374)
  • Obstetrics and Gynecology (486)
  • Occupational and Environmental Health (565)
  • Oncology (1314)
  • Ophthalmology (397)
  • Orthopedics (145)
  • Otolaryngology (235)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (341)
  • Pediatrics (776)
  • Pharmacology and Therapeutics (328)
  • Primary Care Research (294)
  • Psychiatry and Clinical Psychology (2390)
  • Public and Global Health (4987)
  • Radiology and Imaging (892)
  • Rehabilitation Medicine and Physical Therapy (520)
  • Respiratory Medicine (680)
  • Rheumatology (307)
  • Sexual and Reproductive Health (253)
  • Sports Medicine (244)
  • Surgery (296)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)